UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
or

Moderna Inc (MRNA)

Moderna Inc (MRNA)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
25.74 +0.61 (+2.43%) 04/22/25 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 26.04 +0.30 (+1.17%) 19:58 ET
Quote Overview for Tue, Apr 22nd, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
24.87
Day High
25.84
Open 25.27
Previous Close 25.13 25.13
Volume 5,497,500 5,497,500
Avg Vol 9,828,760 9,828,760
Stochastic %K 35.91% 35.91%
Weighted Alpha -76.50 -76.50
5-Day Change -1.06 (-3.96%) -1.06 (-3.96%)
52-Week Range 23.15 - 170.47 23.15 - 170.47
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 9,715,835
  • Shares Outstanding, K 386,623
  • Annual Sales, $ 3,236 M
  • Annual Income, $ -3,561 M
  • EBIT $ -3,945 M
  • EBITDA $ -3,851 M
  • 60-Month Beta 2.23
  • Price/Sales 2.95
  • Price/Cash Flow N/A
  • Price/Book 0.87

Options Overview Details

View History
  • Implied Volatility 83.19% ( -5.94%)
  • Historical Volatility 66.85%
  • IV Percentile 89%
  • IV Rank 65.92%
  • IV High 104.55% on 04/08/25
  • IV Low 41.88% on 05/17/24
  • Put/Call Vol Ratio 0.50
  • Today's Volume 22,507
  • Volume Avg (30-Day) 77,304
  • Put/Call OI Ratio 0.73
  • Today's Open Interest 765,829
  • Open Int (30-Day) 800,493

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 26 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -2.91
  • Number of Estimates 10
  • High Estimate -1.26
  • Low Estimate -3.60
  • Prior Year -3.07
  • Growth Rate Est. (year over year) +5.21%

Price Performance

See More
Period Period Low Period High Performance
1-Month
23.15 +11.19%
on 04/07/25
Period Open: 32.66
34.87 -26.18%
on 03/24/25
-6.92 (-21.19%)
since 03/21/25
3-Month
23.15 +11.19%
on 04/07/25
Period Open: 38.50
45.40 -43.30%
on 01/24/25
-12.76 (-33.14%)
since 01/22/25
52-Week
23.15 +11.19%
on 04/07/25
Period Open: 104.46
170.47 -84.90%
on 05/24/24
-78.72 (-75.36%)
since 04/22/24

Most Recent Stories

More News
What to Expect From Moderna's Q1 2025 Earnings Report

Moderna is scheduled to report its first-quarter results next month, and analysts expect a single-digit earnings growth.

XLV : 135.06 (+1.88%)
$SPX : 5,287.76 (+2.51%)
MRNA : 25.74 (+2.43%)
Where Will Moderna Be in 5 Years?

In the early days of the COVID-19 pandemic, Moderna (NASDAQ: MRNA) was a top performer, from both a share-price and an earnings perspective. As one of the leading coronavirus vaccine companies, the biotech...

MRNA : 25.74 (+2.43%)
Bloom Energy, Rogers, 3D Systems, Moderna, and EchoStar Stocks Trade Down, What You Need To Know

Bloom Energy, Rogers, 3D Systems, Moderna, and EchoStar Stocks Trade Down, What You Need To Know

BE : 16.88 (+3.05%)
DDD : 1.7900 (+0.56%)
ROG : 55.23 (+2.18%)
SATS : 21.31 (+1.48%)
MRNA : 25.74 (+2.43%)
Unpacking Q4 Earnings: AbbVie (NYSE:ABBV) In The Context Of Other Therapeutics Stocks

Unpacking Q4 Earnings: AbbVie (NYSE:ABBV) In The Context Of Other Therapeutics Stocks

SRPT : 59.31 (+7.39%)
BMRN : 61.50 (+4.86%)
ABBV : 173.78 (+2.13%)
MRNA : 25.74 (+2.43%)
AMGN : 278.40 (+1.72%)
Novavax Retail Traders Rally In Defense After RFK Jr.'s COVID-19 Vaccine Skepticism Sends Stock Tumbling

Kennedy singled out the Novavax COVID-19 shot's single-antigen composition as the reason behind the delay in granting full approval.

NVAX : 6.25 (+3.99%)
MRNA : 25.74 (+2.43%)
PFE : 22.53 (+2.22%)
BNTX : 104.68 (+2.82%)
Moderna to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025

CAMBRIDGE, MA / ACCESS Newswire / April 10, 2025 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, May 1, 2025 to report its...

MRNA : 25.74 (+2.43%)
PacBio (PACB) and Hims & Hers Health (HIMS), 10x Genomics (TXG), Moderna (MRNA) Shares Are Soaring, What You Need To Know

PacBio (PACB) and Hims & Hers Health (HIMS), 10x Genomics (TXG), Moderna (MRNA) Shares Are Soaring, What You Need To Know

TXG : 7.96 (+3.65%)
PACB : 1.1700 (+2.63%)
HIMS : 25.35 (-1.90%)
MRNA : 25.74 (+2.43%)
Why Moderna Stock Was Down 31.8% in Q1 as the S&P 500 Had Its Worst Quarter Since 2022

The first quarter of 2025 was a tough one. The S&P 500 lost 4.6%, and the Nasdaq Composite lost 10.4%. Following the trend, shares of Moderna (NASDAQ: MRNA) slid 31.8% in the first three months of the...

COMP : 6.95 (+1.31%)
MRNA : 25.74 (+2.43%)
Spotting Winners: United Therapeutics (NASDAQ:UTHR) And Therapeutics Stocks In Q4

Spotting Winners: United Therapeutics (NASDAQ:UTHR) And Therapeutics Stocks In Q4

BMRN : 61.50 (+4.86%)
VRTX : 490.47 (+2.71%)
MRNA : 25.74 (+2.43%)
UTHR : 292.82 (+3.01%)
BIIB : 118.89 (+2.06%)
Moderna to Showcase Extensive Infectious Disease Research at ESCMID 2025

CAMBRIDGE, MA / ACCESS Newswire / April 7, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will present research across multiple infectious disease areas, including COVID-19, influenza,...

MRNA : 25.74 (+2.43%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Moderna, Inc. is a clinical-stage pharmaceutical company, primarily focused on discovering and developing messenger RNA (mRNA) based therapies. The company's mRNA based COVID-19 vaccine, Spikevax (mRNA-1273), is approved for use in adults in the United States. The vaccine is also authorized for emergency...

See More

Key Turning Points

3rd Resistance Point 27.07
2nd Resistance Point 26.45
1st Resistance Point 26.10
Last Price 25.74
1st Support Level 25.13
2nd Support Level 24.51
3rd Support Level 24.16

See More

52-Week High 170.47
Fibonacci 61.8% 114.19
Fibonacci 50% 96.81
Fibonacci 38.2% 79.43
Last Price 25.74
52-Week Low 23.15

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Unlock High-Probability Trade Setups: Master Fractals & Time Frames Like a Pro